Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.11.2015 | Epidemiology

onlineDeCISion.org: a web-based decision aid for DCIS treatment

verfasst von: Elissa M. Ozanne, Katharine H. Schneider, Djøra Soeteman, Natasha Stout, Deborah Schrag, Michael Fordis, Rinaa S. Punglia

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Women diagnosed with DCIS face complex treatment decisions and often do so with inaccurate and incomplete understanding of the risks and benefits involved. Our objective was to create a tool to guide these decisions for both providers and patients. We developed a web-based decision aid designed to provide clinicians with tailored information about a patient’s recurrence risks and survival outcomes following different treatment strategies for DCIS. A theoretical framework, microsimulation model (Soeteman et al., J Natl Cancer 105:774–781, 2013) and best practices for web-based decision tools guided the development of the decision aid. The development process used semi-structured interviews and usability testing with key stakeholders, including a diverse group of multidisciplinary clinicians and a patient advocate. We developed onlineDeCISion.​org to include the following features that were rated as important by the stakeholders: (1) descriptions of each of the standard treatment options available; (2) visual projections of the likelihood of time-specific (10-year and lifetime) breast-preservation, recurrence, and survival outcomes; and (3) side-by-side comparisons of down-stream effects of each treatment choice. All clinicians reviewing the decision aid in usability testing were interested in using it in their clinical practice. The decision aid is available in a web-based format and is planned to be publicly available. To improve treatment decision making in patients with DCIS, we have developed a web-based decision aid onlineDeCISion.​org that conforms to best practices and that clinicians are interested in using in their clinics with patients to better inform treatment decisions.
Literatur
1.
Zurück zum Zitat Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS (2013) Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst 105(11):774–781PubMedCentralCrossRefPubMed Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS (2013) Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst 105(11):774–781PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. Cancer J Clin 63(1):11–30CrossRef Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. Cancer J Clin 63(1):11–30CrossRef
3.
Zurück zum Zitat Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC
4.
Zurück zum Zitat Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387CrossRefPubMed Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387CrossRefPubMed
5.
Zurück zum Zitat Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418CrossRefPubMed Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418CrossRefPubMed
6.
Zurück zum Zitat Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536–543CrossRefPubMed Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536–543CrossRefPubMed
7.
Zurück zum Zitat Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102CrossRefPubMed Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102CrossRefPubMed
8.
Zurück zum Zitat Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCentralCrossRefPubMed Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Baxter NN, Virnig BA, Durham SB, Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96(6):443–448CrossRefPubMed Baxter NN, Virnig BA, Durham SB, Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96(6):443–448CrossRefPubMed
10.
Zurück zum Zitat Rakovitch E, Pignol JP, Chartier C, Hanna W, Kahn H, Wong J, Mai V, Paszat L (2007) The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 101(3):335–347CrossRefPubMed Rakovitch E, Pignol JP, Chartier C, Hanna W, Kahn H, Wong J, Mai V, Paszat L (2007) The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 101(3):335–347CrossRefPubMed
11.
Zurück zum Zitat Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCentralCrossRefPubMed Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson NE et al (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. San Antonio Breast Cancer 71:S4–S6 Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson NE et al (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. San Antonio Breast Cancer 71:S4–S6
13.
Zurück zum Zitat Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710PubMedCentralCrossRefPubMed Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K et al (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251CrossRefPubMed Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K et al (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251CrossRefPubMed
15.
Zurück zum Zitat Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma-in situ of the breast: a critical review of the literature. J Clin Oncol 20(11):2736–2744CrossRefPubMed Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma-in situ of the breast: a critical review of the literature. J Clin Oncol 20(11):2736–2744CrossRefPubMed
16.
Zurück zum Zitat Ravdin PM, Siminoff IA, Harvey JA (1998) Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16(2):515–521PubMed Ravdin PM, Siminoff IA, Harvey JA (1998) Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16(2):515–521PubMed
17.
Zurück zum Zitat Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Legare F, Thomson R (2011) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 5(10):CD001431 Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Legare F, Thomson R (2011) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 5(10):CD001431
18.
Zurück zum Zitat Hoffman AS, Volk RJ, Saarimaki A, Stirling C, Li LC, Harter M, Kamath GR, Llewellyn-Thomas H (2013) Delivering patient decision aids on the Internet: definitions, theories, current evidence, and emerging research areas. BMC Med Inform Decis Mak 13(Suppl 2):S13PubMedCentralCrossRefPubMed Hoffman AS, Volk RJ, Saarimaki A, Stirling C, Li LC, Harter M, Kamath GR, Llewellyn-Thomas H (2013) Delivering patient decision aids on the Internet: definitions, theories, current evidence, and emerging research areas. BMC Med Inform Decis Mak 13(Suppl 2):S13PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Rippon I, Steptoe A (2015) Feeling old vs being old: associations between self-perceived age and mortality. JAMA Intern Med 175(2):307–309CrossRefPubMed Rippon I, Steptoe A (2015) Feeling old vs being old: associations between self-perceived age and mortality. JAMA Intern Med 175(2):307–309CrossRefPubMed
20.
Zurück zum Zitat Love N (2005) Management of breast cancer in the adjuvant and metastatic setts. Patterns Care Med Oncol 2(3) Love N (2005) Management of breast cancer in the adjuvant and metastatic setts. Patterns Care Med Oncol 2(3)
21.
Zurück zum Zitat Peele PB, Siminoff LA, Xu Y, Ravdin PM (2005) Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 25(3):301–307CrossRefPubMed Peele PB, Siminoff LA, Xu Y, Ravdin PM (2005) Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 25(3):301–307CrossRefPubMed
22.
Zurück zum Zitat Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP (2001) Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Women’s Health Gender-Based Med 10(6):589–598CrossRef Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP (2001) Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Women’s Health Gender-Based Med 10(6):589–598CrossRef
23.
Zurück zum Zitat van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556CrossRefPubMed van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556CrossRefPubMed
24.
Zurück zum Zitat Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, Pritchard KI, Ho C, Redelmeier DA (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293CrossRefPubMed Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, Pritchard KI, Ho C, Redelmeier DA (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293CrossRefPubMed
25.
Zurück zum Zitat Jagsi R, Hayman J (2013) Informing patient decisions regarding management of ductal carcinoma in situ. J Natl Cancer Inst 105(11):758–759CrossRefPubMed Jagsi R, Hayman J (2013) Informing patient decisions regarding management of ductal carcinoma in situ. J Natl Cancer Inst 105(11):758–759CrossRefPubMed
26.
Zurück zum Zitat Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27(2):214–219CrossRefPubMed Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27(2):214–219CrossRefPubMed
27.
Zurück zum Zitat Han PK (2013) Conceptual, methodological, and ethical problems in communicating uncertainty in clinical evidence. Med Care Res Rev 70(1 Suppl):14S–36SPubMedCentralCrossRefPubMed Han PK (2013) Conceptual, methodological, and ethical problems in communicating uncertainty in clinical evidence. Med Care Res Rev 70(1 Suppl):14S–36SPubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E (2008) Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer 8(3):275–280CrossRefPubMed Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E (2008) Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer 8(3):275–280CrossRefPubMed
29.
Zurück zum Zitat Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA et al (2010) National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22–24. J Natl Cancer Inst 102(3):161–169CrossRefPubMed Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA et al (2010) National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22–24. J Natl Cancer Inst 102(3):161–169CrossRefPubMed
Metadaten
Titel
onlineDeCISion.org: a web-based decision aid for DCIS treatment
verfasst von
Elissa M. Ozanne
Katharine H. Schneider
Djøra Soeteman
Natasha Stout
Deborah Schrag
Michael Fordis
Rinaa S. Punglia
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3605-y

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.